What Avammune Therapeutics does

Avammune Therapeutics is a clinical-stage, pre-revenue biopharmaceutical company developing first-in-class and best-in-class small molecule immunotherapies for hard-to-treat solid tumors. The company operates a modality-agnostic discovery platform that integrates bioinformatics, computational chemistry-driven target identification, a proprietary small molecule library focused on DNA/RNA-binding proteins, and high-throughput chemistry and biology to compress design-build-test cycles. Its pipeline comprises three differentiated candidates: AVA-NP-695, a best-in-class ENPP1 inhibitor designed to restore STING pathway activation and convert cold tumors into immune-responsive hot tumors; AVA-ADR, a first-in-class ADAR1 p150 Zα-domain inhibitor intended to reverse resistance to checkpoint inhibitors; and AVA-ERL, a first-in-class tumor-targeted radioligand therapy for precision tumor cell killing with minimal healthy-tissue exposure.

The company is headquartered in Philadelphia, Pennsylvania, with a research and operating entity, Avammune Lifesciences Private Limited, in Bangalore, India. It was founded in 2020 by Arun B. Papaiah (CEO), Aditya Kulkarni (CSO), and Srinivasan Namala (Director), a team with prior biotech ventures including Oraxion Therapeutics (whose technology platform was licensed to a US biotech for $125 million) and Aten Porus Lifesciences (which was sold to Bain Private Equity in 2023). Avammune is supported by a Scientific Advisory Board drawn from Oxford, UCSF, the University of Chicago, the Tisch Cancer Institute, and the University of Queensland, and has published its mechanistic work in peer-reviewed journals including Frontiers in Immunology, Molecules, and Bioorganic Chemistry, with regular presence at SITC, AACR, and ASCO conferences.

Avammune's commercial model is pre-revenue and built around POC-driven partnerships: the company seeks to advance its candidates through preclinical and early clinical development and then monetize them via licensing, co-development, or royalty agreements with larger biopharma counterparties rather than building independent commercial infrastructure. The eventual go-to-market in oncology is expected to rely on enterprise field sales to oncologists, hospitals, and cancer treatment centers. In May 2025 the company closed a $12 million Series A co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I, with participation from IvyCap Ventures and 1Crowd, to fund clinical development of AVA-NP-695 and pipeline expansion into autoimmune disorders.

Name

Avammune Therapeutics

Legal name

Avammune Therapeutics, Inc.

Website

https://avammune.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Avammune Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company developing first-in-class and best-in-class small molecule immunotherapies for hard-to-treat solid tumors. Its modality-agnostic platform integrates bioinformatics, computational chemistry, and high-throughput biology across three candidates targeting ENPP1, ADAR1 p150, and tumor radioligands.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Small molecule drugs
• Immuno-oncology therapy
• Radioligand therapy
• Drug discovery platform
• Cancer therapeutics

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-Revenue Stage: Avammune is a pre-revenue R&D-stage biopharmaceutical company focused on developing novel cancer therapeutics. The company has not yet commercialized any products and is currently in the discovery and preclinical/early clinical development stage with its lead drug candidate AVA-NP-695.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Avammune Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops first-in-class and best-in-class small molecule immunotherapies for hard-to-treat solid tumors. Its pipeline comprises three drug candidates: AVA-NP-695 (an ENPP1 inhibitor for immune modulation), AVA-ADR (an ADAR1 p150 inhibitor to reverse checkpoint resistance), and AVA-ERL (a tumor-targeted radioligand therapy). The company operates a multi-modal discovery platform integrating bioinformatics, computational chemistry, and a proprietary small molecule library targeting DNA/RNA-binding proteins, and seeks early proof-of-concept-driven co-development partnerships.

Product overview

Avammune Therapeutics is an R&D-driven drug discovery company developing novel modality-agnostic best-in-class and first-in-class small molecule therapies for hard-to-treat solid tumors. The company's portfolio consists of three differentiated drug candidates: AVA-NP-695 (ENPP1 inhibitor, Best-in-Class for innate immune modulation), AVA-ADR (ADAR1 p150 inhibitor, First-in-Class for targeted therapies), and AVA-ERL (Tumor-targeted Radioligand Therapy, First-in-Class for radiopharmaceutical precision medicine). The pipeline targets fundamental biological mechanisms that enable cancers to evade the immune system and develop resistance to therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• AVA-NP-695
• AVA-ADR
• AVA-ERL

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered strategic and supporting.

• University of OxfordstrategicStrategic or Co-development PartnerAcademic partnership with Professor Jan Rehwinkel (Professor of Innate Immunology) and Professor Paul Brennan (Professor of Medicinal Chemistry) serving on Avammune's Scientific Advisory Board.
• UCSF (University of California, San Francisco)strategicStrategic or Co-development PartnerAcademic partnership with Professor Alejandro Sweet-Cordero (Chief of Pediatric Oncology and Director of UCSF Molecular Oncology Initiative) serving on the Scientific Advisory Board. Collaboration on sarcoma and advanced cancer research.
• University of ChicagosupportingStrategic or Co-development PartnerAcademic partner with Dr. Akash Patnaik (Deputy Section Chief for Translational Research, UCCCC) on Scientific Advisory Board, providing expertise in immunotherapy and translational research.
• University of QueenslandsupportingStrategic or Co-development PartnerAcademic research partner listed on company website partnerships section.
• Tisch Cancer InstitutestrategicStrategic or Co-development PartnerAcademic partnership with Professor Thomas Marron (Director, Early Phase Trials Unit & Associate Professor of Medicine) serving on Scientific Advisory Board, focusing on cancer immunotherapies and Phase 1/2 clinical trials.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Exscientia: AI-enabled small-molecule drug discovery company with oncology and immunology pipeline assets; directly comparable on platform methodology (AI-driven target ID and design) and pipeline stage.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with computational chemistry to advance small-molecule candidates into the clinic; comparable in platform architecture though at substantially larger scale.
• Compugen: Computational biology company using AI/ML for target identification in immuno-oncology; comparable in using bioinformatics-driven discovery to identify novel tumor immunology targets, similar to Avammune's STING-pathway approach.
• Black Diamond Therapeutics: Precision oncology biotech developing small-molecule therapies against novel targets including those involved in tumor immune evasion; comparable in oncology focus and first-in-class positioning.
• Immuneering: Clinical-stage oncology biotech using computational biology and bioinformatics to develop small-molecule immuno-oncology and MAPK pathway therapies; closely comparable in modality and discovery approach to Avammune.
• Schrodinger: Computational chemistry platform company that partners with pharma and runs an internal pipeline of small-molecule drug candidates; overlaps with Avammune's computational chemistry-driven discovery approach.

Emerging players

• Werewolf Therapeutics: Clinical-stage oncology biotech developing next-generation immuno-oncology therapeutics including INDUKINE and PREDATOR platforms; overlaps with Avammune in tumor immune modulation focus.
• Anaveon: Clinical-stage immuno-oncology company developing cytokine-based therapies targeting the interferon pathway; overlaps with Avammune's focus on type I IFN modulation through ENPP1 inhibition.

Regional players

• ABL Bio: Korea-based clinical-stage immuno-oncology biotech developing bispecific antibodies and novel oncology modalities; relevant comparator given Avammune's India-led operations and similar emerging-market biotech profile.

Broad incumbents

• Arcus Biosciences: Mid-cap immuno-oncology company with multiple clinical-stage programs targeting adenosine pathway and other immune checkpoints; broader portfolio than Avammune but directly relevant in tumor immune modulation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/avammune-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avammune Therapeutics